Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.

Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ

Diabetes care20 Nov 2014Cited by 152 (Europe PMC)

PMID25414155DOI10.2337/dc14-1958PepBankPUB-25414155

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialMechanism
In hypertensive adults with type 2 diabetes, a single liraglutide dose did not significantly change plasma ANP versus placebo.
In plain wordsIn hypertensive adults with type 2 diabetes, one liraglutide dose did not change blood levels of atrial natriuretic peptide compared with placebo.
Peptide
Liraglutide
Outcome
No significant changePlasma ANP after a single dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
0.6 mg single dose · 4 hAs given in this study (human).
Source sentences
Summary
Plasma ANP levels did not change significantly after acute (+16.72 pg/mL, P = 0.24, 95% CI [-12.1, +45.5] at 2 h) or chronic (-17.42 pg/mL, 95% CI [-36.0, +1.21] at 2 h) liraglutide administration.
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide or placebo was administered for 3 weeks to hypertensive subjects with type 2 diabetes in a double-blinded, randomized, placebo-controlled crossover clinical trial in the ambulatory setting.
Report a problemFND-2541415501
02HumanRandomized controlled trialMechanism
In hypertensive adults with type 2 diabetes, 21 days of liraglutide did not significantly change plasma ANP versus placebo.
In plain wordsIn hypertensive adults with type 2 diabetes, 21 days of liraglutide did not change blood levels of atrial natriuretic peptide compared with placebo.
Peptide
Liraglutide
Outcome
No significant changePlasma ANP after 21 days
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
titrated to 1.8 mg · 21 daysAs given in this study (human).
Source sentences
Summary
Plasma ANP levels did not change significantly after acute (+16.72 pg/mL, P = 0.24, 95% CI [-12.1, +45.5] at 2 h) or chronic (-17.42 pg/mL, 95% CI [-36.0, +1.21] at 2 h) liraglutide administration.
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide or placebo was administered for 3 weeks to hypertensive subjects with type 2 diabetes in a double-blinded, randomized, placebo-controlled crossover clinical trial in the ambulatory setting.
Report a problemFND-2541415502
03HumanRandomized controlled trialEfficacy outcome
In hypertensive adults with type 2 diabetes, 21 days of liraglutide significantly increased 24-h and nighttime urinary sodium excretion versus placebo.
In plain wordsIn hypertensive adults with type 2 diabetes, liraglutide increased the amount of sodium passed in urine compared with placebo.
Peptide
Liraglutide
Outcome
Increase24-h and nighttime urinary sodium excretion
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
titrated to 1.8 mg · 21 daysAs given in this study (human).
Source sentences
Summary
Liraglutide significantly increased 24-h and nighttime urinary sodium excretion
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide or placebo was administered for 3 weeks to hypertensive subjects with type 2 diabetes in a double-blinded, randomized, placebo-controlled crossover clinical trial in the ambulatory setting.
Report a problemFND-2541415503
04HumanRandomized controlled trialEfficacy outcome
In hypertensive adults with type 2 diabetes, 24-h systolic blood pressure was not significantly different with liraglutide than with placebo.
In plain wordsIn hypertensive adults with type 2 diabetes, liraglutide did not change 24-hour systolic blood pressure compared with placebo.
Peptide
Liraglutide
Outcome
No significant change24-h systolic blood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
titrated to 1.8 mg · 21 daysAs given in this study (human).
Source sentences
Summary
24-h systolic BP was not significantly different.
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide or placebo was administered for 3 weeks to hypertensive subjects with type 2 diabetes in a double-blinded, randomized, placebo-controlled crossover clinical trial in the ambulatory setting.
Report a problemFND-2541415504
05HumanRandomized controlled trialSafety outcome
In hypertensive adults with type 2 diabetes, liraglutide gave small but significant increases in 24-h and nighttime diastolic blood pressure.
In plain wordsIn hypertensive adults with type 2 diabetes, liraglutide caused small rises in diastolic blood pressure over 24 hours and at night.
Peptide
Liraglutide
Outcome
Increase24-h and nighttime diastolic blood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
titrated to 1.8 mg · 21 daysAs given in this study (human).
Source sentences
Summary
Small but significant increases in 24-h and nighttime diastolic BP and HR were observed with liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide or placebo was administered for 3 weeks to hypertensive subjects with type 2 diabetes in a double-blinded, randomized, placebo-controlled crossover clinical trial in the ambulatory setting.
Report a problemFND-2541415505
06HumanRandomized controlled trialSafety outcome
In hypertensive adults with type 2 diabetes, liraglutide gave small but significant increases in 24-h and nighttime heart rate.
In plain wordsIn hypertensive adults with type 2 diabetes, liraglutide caused small rises in heart rate over 24 hours and at night.
Peptide
Liraglutide
Outcome
Increase24-h and nighttime heart rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
titrated to 1.8 mg · 21 daysAs given in this study (human).
Source sentences
Summary
Small but significant increases in 24-h and nighttime diastolic BP and HR were observed with liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide or placebo was administered for 3 weeks to hypertensive subjects with type 2 diabetes in a double-blinded, randomized, placebo-controlled crossover clinical trial in the ambulatory setting.
Report a problemFND-2541415506
07HumanRandomized controlled trialEfficacy outcome
In hypertensive adults with type 2 diabetes, body weight was lower with liraglutide.
In plain wordsIn hypertensive adults with type 2 diabetes, body weight was lower with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
titrated to 1.8 mg · 21 daysAs given in this study (human).
Source sentences
Summary
Body weight, HbA1c, and cholesterol were lower
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide or placebo was administered for 3 weeks to hypertensive subjects with type 2 diabetes in a double-blinded, randomized, placebo-controlled crossover clinical trial in the ambulatory setting.
Report a problemFND-2541415507
08HumanRandomized controlled trialEfficacy outcome
In hypertensive adults with type 2 diabetes, HbA1c was lower with liraglutide.
In plain wordsIn hypertensive adults with type 2 diabetes, HbA1c was lower with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
titrated to 1.8 mg · 21 daysAs given in this study (human).
Source sentences
Summary
Body weight, HbA1c, and cholesterol were lower
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide or placebo was administered for 3 weeks to hypertensive subjects with type 2 diabetes in a double-blinded, randomized, placebo-controlled crossover clinical trial in the ambulatory setting.
Report a problemFND-2541415508
09HumanRandomized controlled trialEfficacy outcome
In hypertensive adults with type 2 diabetes, cholesterol was lower with liraglutide.
In plain wordsIn hypertensive adults with type 2 diabetes, cholesterol was lower with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseCholesterol
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Cardiovascular
Studied dose
titrated to 1.8 mg · 21 daysAs given in this study (human).
Source sentences
Summary
Body weight, HbA1c, and cholesterol were lower
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide or placebo was administered for 3 weeks to hypertensive subjects with type 2 diabetes in a double-blinded, randomized, placebo-controlled crossover clinical trial in the ambulatory setting.
Report a problemFND-2541415509
10HumanRandomized controlled trialSafety outcome
In hypertensive adults with type 2 diabetes, office-measured heart rate was transiently increased, for up to 4 h, with liraglutide.
In plain wordsIn hypertensive adults with type 2 diabetes, liraglutide briefly raised office heart rate, for up to 4 hours.
Peptide
Liraglutide
Outcome
IncreaseOffice-measured heart rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · up to 4 hAs given in this study (human).
Source sentences
Summary
office-measured HR was transiently increased (for up to 4 h) with liraglutide administration.
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide or placebo was administered for 3 weeks to hypertensive subjects with type 2 diabetes in a double-blinded, randomized, placebo-controlled crossover clinical trial in the ambulatory setting.
Report a problemFND-2541415510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01755572

Blood Pressure Outcomes With Liraglutide Therapy

Mount Sinai Hospital, Canadan = 22Jan 2013 to Mar 2014

Type 2 Diabetes · Systolic Hypertension

Trial page ClinicalTrials.govUpdated 25 Mar 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.